The vaccine currently under development at Johnsons & Johnsons (J&J) was found to incite a strong immune response in monkeys infected with novel coronavirus after just a single jab.
The experimental vaccine developed by the US-based drugmaker was tested on macaque monkeys, Bloomberg reports, and the vaccine protected the primate with just one shot in the pre-clinical study.
According to the report, five out of six pathogens were exposed to the novel coronavirus and were immune to the same after a single jab, researchers found. Seven different vaccine prototypes were jabbed to 52 macaques.
Johnson & Johnson’s vaccine potentially gains on the number of other vaccines presently under development across the world, most of which have been found to incite considerable results after two doses.
The finding was published in the medical journal Nature. “The findings published today are a very important part of the profile that we can bring to the table over the next few weeks as we work with different countries on reaching advanced agreements,” J&J’s chief scientific officer, Paul Stoffels said in an interview.
J&J’s vaccine is based on a human adenovirus, one that causes the common cold. The company started human clinical trials on July 22nd in Belgium and the US.
J&J’s trajectory for testing the efficacy of the dose will be to-folds, according to a Bloomberg report. The first trial will involve one shot of the vaccine and the second part will involve one sh and a booster to the 1000 adults.
According to Stoffels, J&J’s shot-plus-booster approach to immunizing holds up better against other ways of vaccinating.
America’s top infectious disease expert Dr. Anthony Facai, speaking at the virtual Indian Council of Medical Research’s (ICMR) International Symposium on Novel Ideas in Science and Ethics of Vaccines against COVID-19 pandemic said deliberately exposing humans to the novel COVID-19 in the absence of proven treatment is not necessary, unethical, The Print reports.
There has been a considerable amount of uncertainty on the nature of the virus and how will it react to the vaccinations, with scientists fearing that doses may not be immune in the long run.
“I hope we can protect people for a long time with one, two, or even three boosters. Hopefully, by then, it will be done,” Stoffels said about J&J approach to immunizing.